Clinical Status and Progress of Immunotherapy for Lung Cancer from Immune Checkpoints to Individualized Treatment Strategies
Lung cancer is a malignant tumor with high incidence and mortality,among which non-small cell lung cancer(NSCLC)accounts for over 80%.In recent years,immune checkpoint inhibitors(ICI)have shown significant clinical benefits as a new type of immunotherapy in the first or second line treatment of advanced NSCLC,improving the survival and quality of life of patients.However,there are still some patients who are not sensitive to ICI or develop resistance.Therefore,finding effective predictive biomarkers and developing personalized treatment strategies are important directions for current lung cancer immunotherapy.This article reviews the immunobiological characteristics of lung cancer,the clinical application of ICI in lung cancer,the predictive biomarkers of ICI efficacy,and the development direction of individualized treatment strategies.It also explores the future prospects of immunotherapy for lung cancer.
万方数据
维普
